## BACKGROUND. The health-related functioning of patients with cancer is compromised by several factors, including the disease process, treatment, and the various symptoms that are produced by both disease and treatment. This study was designed to specify the relationship between patients' pain se
The Influence of Personal Expectations on Cancer Patients' Reports of Health-Related Quality of Life
β Scribed by George J. Wan; Michael A. Counte; David F. Cella
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 136 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1057-9249
No coin nor oath required. For personal study only.
β¦ Synopsis
The role of personal expectations on reports of health-related quality of life (HRQL) in the context of a set of other variables commonly thought to affect patient report of HRQL was examined. The complete set of predictor variables included: (1) patient factors including age, gender, race, education, income, insurance type, living arrangement and expectations; and (2) clinical factors namely performance status rating (PSR), diagnosis and disease stage. The outcome measures included five dimensions of HRQL (relationship with physician, physical, social, emotional and functional well being) and an overall measure of HRQL. Five variables (PSR, expectation rating, age, living arrangement and managed care enrollment) exerted significant effects on the summated rating of HRQL. Older cancer patients, those living with others, those enrolled in managed care organizations and those who report betterthan-expected experience are more likely to have a higher overall HRQL. In addition to treating the disease itself, quality of life can possibly be enhanced by narrowing the disparities between individuals' expectations and what actually occurs. Patients would likely therefore benefit from being encouraged to set and maintain realistic goals concerning their cancer prognosis and treatment process.
π SIMILAR VOLUMES
Measurement of pediatric cancer patients' health-related quality of life (HRQL) in phase III randomized, controlled clinical trials is being recognized increasingly as an essential component in evaluating the comprehensive health outcomes of modern anti-neoplastic treatment protocols. Use of a brief